ALSO READJapan's Takeda weighs bid for drugmaker Shire Japan's Takeda considering approach for British drugmaker Shire Drugmaker Shire soars as Japan's Takeda considers bid Japanese drugmaker Takeda shares tumble as company considers bid for Shire Sun Pharma settles patent litigation with Ironwood, Allergan
LONDON (Reuters) - Shire, the London-listed pharmaceutical company which specialises in rare diseases, said on Monday it was selling its oncology business to French drug maker Servier for $2.4 billion.
Shire, which is a possible bid target for Japan's largest drugmaker Takeda Pharmaceutical, said it would consider returning the proceeds of the sale to shareholders through a buyback.
(Reporting by Sarah Young; editing by Kate Holton)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)